<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:tp="http://www.plazi.org/taxpub" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">126</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:7099c1e0-efdc-54e4-93b7-b6ecd3612deb</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Bulgarian Society of Medical Sciences Journal</journal-title>
        <abbrev-journal-title xml:lang="en">BSMS</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2815-4959</issn>
      <issn pub-type="epub">3033-1471</issn>
      <publisher>
        <publisher-name>Bulgarian Society of Medical Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/bsms.8.154296</article-id>
      <article-id pub-id-type="publisher-id">154296</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Therapeutics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>C-reactive protein and cardiac repolarization in cirrhosis</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Emilova</surname>
            <given-names>Niya</given-names>
          </name>
          <email xlink:type="simple">niaemilova@yahoo.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0003-1878-9807</uri>
          <xref ref-type="aff" rid="A1">1</xref>
          <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Dineva</surname>
            <given-names>Dobrinka</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0005-1019-128X</uri>
          <xref ref-type="aff" rid="A2">2</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Moneva-Sakelarieva</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kobakova</surname>
            <given-names>Yozlem</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Chaneva</surname>
            <given-names>Mariya</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
          <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Ionchev</surname>
            <given-names>Ionko</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Slaveva</surname>
            <given-names>Diana</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
          <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Popova</surname>
            <given-names>Mihaela</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Tododrov</surname>
            <given-names>Radoslav</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kostov</surname>
            <given-names>Konstantin</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Sarakostova</surname>
            <given-names>Silvia</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
          <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
          <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgaria</addr-line>
        <institution>University Emergency Medicine Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">Department of Clinical Laboratory, University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgaria</addr-line>
        <institution>Department of Clinical Laboratory, University Emergency Medicine Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">Clinic of Internal Medicine, University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgaria</addr-line>
        <institution>Clinic of Internal Medicine, University Emergency Medicine Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A4">
        <label>4</label>
        <addr-line content-type="verbatim">Department of General, Visceral and Emergency Surgery, University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgariа</addr-line>
        <institution>Department of General, Visceral and Emergency Surgery, University Emergency Medicine Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A5">
        <label>5</label>
        <addr-line content-type="verbatim">Clinic of Toxicology, University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgaria</addr-line>
        <institution>Clinic of Toxicology, University Emergency Medicine Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p><bold>Corresponding author</bold>: Niya Emilova, University Emergency Medicine Hospital “Pirogov”, Sofia, Bulgaria; E-mail: <email xlink:type="simple">niaemilova@yahoo.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>02</month>
        <year>2026</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>e154296</elocation-id>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/FE6ADDF7-039F-5160-ACF0-D5A6D65F647E">FE6ADDF7-039F-5160-ACF0-D5A6D65F647E</uri>
      <uri content-type="zenodo_dep_id" xlink:href="https://zenodo.org/record/0">0</uri>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>03</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>04</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Niya Emilova, Dobrinka Dineva, Maria Moneva-Sakelarieva, Yozlem Kobakova, Mariya Chaneva, Ionko Ionchev, Diana Slaveva, Mihaela Popova, Radoslav Tododrov, Konstantin Kostov, Silvia Sarakostova</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p><bold>Introduction</bold>: The systolic and diastolic function of the left ventricle and the activation of the autonomic nervous system are main determinants of ventricular repolarisation. <bold>Purpose</bold>: We conducted an analysis of the association of inflammatory markers with indices of ventricular repolarisation (heart rate, duration of repolarisation period - QTc, dispersion of repolarisation - <abbrev xlink:title="QT dispersion">QTcd</abbrev>) as well as with prognostic scores in patients with alcoholic cirrhosis. A group of patients with chronic coronary disease (<abbrev xlink:title="chronic coronary disease">CAD</abbrev>) and another group with acute myocardial infarction (<abbrev xlink:title="acute myocardial infarction">AMI</abbrev>) were used for comparison. <bold>Results</bold>: Procalcitonin correlated positively as tendency with Child-Pugh score in the patient group with alcoholic cirrhosis on therapy. Only <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> showed a trend for association with non-homogenous repolarization in the group of male patients with cirrhosis on therapy. Higher white blood count (<abbrev xlink:title="acute myocardial infarction">WBC</abbrev>) was marginally related to shorter minimal repolarisation periods and with dispersion of repolarisation in <abbrev xlink:title="acute myocardial infarction">AMI</abbrev>. Higher <abbrev xlink:title="C-reactive protein">CRP</abbrev> was related as tendency with shorter minimal repolarisation periods, longer maximal repolarisation periods and correlated significantly positively with higher dispersion of repolarisation in <abbrev xlink:title="acute myocardial infarction">AMI</abbrev>. Higher levels of <abbrev xlink:title="C-reactive protein">CRP</abbrev> also correlated with prolonged maximal repolarization in stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev>. <bold>Conclusions</bold>: The count of white blood cells and procalcitonin are associated with risk of complications in alcoholic cirrhosis. In patients with cirrhosis and infection on therapy, <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> is specific marker of increased dispersion of repolarisation. In contrast to cirrhosis, <abbrev xlink:title="C-reactive protein">CRP</abbrev> is associated with the risk of ventricular arrhythmias in stable coronary disease, while both <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> correlated with repolarisation indices in acute myocardial infarction.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>White blood cell count</kwd>
        <kwd>C-reactive protein</kwd>
        <kwd>procalcitonin</kwd>
        <kwd>QTc</kwd>
        <kwd>QTcd</kwd>
        <kwd>cirrhosis</kwd>
        <kwd>coronary disease</kwd>
        <kwd>acute myocardial infarction</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="sec1">
        <title>Citation</title>
        <p>Emilova N, Dineva D, Moneva-Sakelarieva M, Kobakova Y, Chaneva M, Ionchev I, Slaveva D, Popova M, Tododrov R, Kostov K, Sarakostova S. C-reactive protein and cardiac repolarization in cirrhosis. Bulgarian Society of Medical Sciences Journal 2026;8:e154296. <ext-link ext-link-type="doi" xlink:href="10.3897/bsms.8.154296">doi: 10.3897/bsms.8.154296</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="sec2">
      <title>Introduction</title>
      <p>QTc is used as a measure of the duration of the period of ventricular repolarization adjusted to extremes in heart rate. The difference between the minimal and maximal QTc termed corrected QT dispersion (<abbrev xlink:title="QT dispersion">QTcd</abbrev>) reflects the dispersion of ventricular repolarization. Increased dispersion of repolarization is considered as prognostic index of the risk of sustained ventricular tachycardia and sudden cardiac death <sup>[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]</sup>. The systolic and diastolic function of the left ventricle and the activation of the autonomic nervous system are main determinants of ventricular repolarisation <sup>[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]</sup>.</p>
      <p>Observational studies in populations of patients with coronary disease suggested associations between repolarisation indices with acute myocardial ischemia, acute myocardial infarction and also with markers of myocardial injury <sup>[<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>]</sup>. <abbrev xlink:title="QT dispersion">QTcd</abbrev> is significantly higher in patients with myocardial infarction and heart failure with previous arrhythmic event <sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup>.</p>
      <p>Alcohol intoxication induces acute myocardial contractile abnormalities <sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup>. Chronic excessive alcohol consumption causes persistent inflammation in liver induced by toxic effect of alcohol on hepatocytes <sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup>. Liver cirrhosis is frequently complicated by bacterial infections <sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup>. Systemic inﬂammatory response was considered as underlying pathophysiological mechanism of left ventricular dysfunction in cases with alcoholic liver disease <sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup>. The duration of cardiac repolarisation (QTc) is usually abnormally long in cirrhosis of higher Child-Pugh and higher <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev> scores. QTc increases with gastrointestinal bleeding, possibly due to related cardiac ischemia <sup>[<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]</sup>. In particular, systemic inflammation can significantly prolong QTc during acute infections, via cytokine-mediated changes in potassium channel expression <sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup>. Similar association, between prolonged QTc with increased inflammatory markers was reported in clinically active autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis <sup>[<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]</sup>.</p>
      <p>Beta-blockers reduce QTc dispersion in patients with chronic heart failure, with greater response in patients with ischemic cardiomyopathy <sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup>. Also, the addition of aldosterone inhibitor (spironolactone) and ACE inhibitor/AT receptor inhibitor significantly improves QT dispersion <sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup>. Beta-blockers and aldosterone inhibitors have same effects in cirrhosis.</p>
      <p>There is limited data regarding arrhythmia risk prediction in cirrhosis and association of inflammation with the risk of ventricular arrhythmia. Our aim was to contrast inflammatory-repolarization relationships across diseases of different system localisation.</p>
    </sec>
    <sec sec-type="Purpose" id="sec3">
      <title>Purpose</title>
      <p>We conducted a retrospective cohort study of the association of inflammatory markers with indices of ventricular repolarisation (heart rate, duration of repolarisation period adjusted to heart rate - QTc, dispersion of repolarisation - <abbrev xlink:title="QT dispersion">QTcd</abbrev>) as well as with prognostic scores in patients with alcoholic cirrhosis. A group of patients with chronic ischemic heart disease and another group with acute myocardial infarction were used for comparison.</p>
    </sec>
    <sec sec-type="materials|methods" id="sec4">
      <title>Material and methods</title>
      <p>A group of 19 male patients with alcoholic liver cirrhosis Child A, B and C class and 26 male patients with stable coronary disease (<abbrev xlink:title="chronic coronary disease">CAD</abbrev>) admitted to Clinic of Internal Medicine of Emergency Medicine Hospital ‘Pirogov’ for infectious exacerbation of disease were analysed. A group of 60 male patients with acute myocardial infarction after primary percutaneous intervention with stent implantation without known infectious complications was used as comparison.</p>
      <p>The diagnosis of liver cirrhosis was made based on the history of alcohol abuse, clinical and ultrasound signs of hepatomegaly, cirrhotic transformation of the liver, portal hypertension, ascites, peripheral oedema, jaundice. The alcoholic etiology of cirrhosis was supported by laboratory markers of persistent liver injury and indirect markers of alcohol consumption: increased mean volume of red blood cells (<abbrev xlink:title="mean volume of red blood cells">MCV</abbrev>), bilirubin, aspartate aminotransferase (<abbrev xlink:title="aspartate aminotransferase">ASAT</abbrev>), γ-glutamyl transferase (<abbrev xlink:title="γ-glutamyl transferase">GGT</abbrev>), ratio of aspartate aminotransferase to alanine aminotransferase (<abbrev xlink:title="aspartate aminotransferase">ASAT</abbrev>/ALAT&gt;1).</p>
      <p>The scores used for the assessment of severity of cirrhosis included FIB-4 index, Child-Turcotte-Pugh (<abbrev xlink:title="Child-Turcotte-Pugh">CTP</abbrev>) score and model of end-stage liver disease (<abbrev xlink:title="model of end-stage liver disease">MELD</abbrev>). They were calculated by means of an electronic calculator (MEDCalc). FIB-4 index is used for initial evaluation of liver fibrosis and combing data of age, <abbrev xlink:title="aspartate aminotransferase">ASAT</abbrev>, ALAT, platelet count of each patient with cirrhosis. Child-Turcotte-Pugh (<abbrev xlink:title="Child-Turcotte-Pugh">CTP</abbrev>) score includes measures of plasma albumin, bilirubin, <abbrev xlink:title="international normalized ratio">INR</abbrev>, data for diagnosed ascites, encephalopathy. This score is most widely used for liver cirrhosis staging but it does not consider renal function <sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup>. <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev> uses the patient’s values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (<abbrev xlink:title="international normalized ratio">INR</abbrev>) to predict survival <sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup>.</p>
      <p>The indices of repolarisation were measured form 12-lead conventional electrocardiography by one investigator. They were adjusted for extremes in heart rate by the use of Bazett’s formula and of an e-calculator (MEDCalc). The duration of repolarisation period was defined by the interval between the beginning of Q-wave to the end of T-wave. The mean value of QT interval measured in all 12 leads was used in this analysis. The difference between the minimal and maximal QTc termed corrected QT dispersion (<abbrev xlink:title="QT dispersion">QTcd</abbrev>) was used as marker of the dispersion of ventricular repolarization.</p>
      <p>The chemiluminescent microparticle immunoassay (<abbrev xlink:title="chemiluminescent microparticle immunoassay">CMIA</abbrev>) technology is used to quantitatively determine procalcitonin (<abbrev xlink:title="procalcitonin">PCT</abbrev>) in human serum and plasma. The principle of the method is described in details elsewhere <sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup>.</p>
      <p>The immunoturbidimetric method for measuring C-reactive protein (<abbrev xlink:title="C-reactive protein">CRP</abbrev>) involves the formation of immunocomplexes between <abbrev xlink:title="C-reactive protein">CRP</abbrev> in the test sample and specific antibodies. These complexes cause turbidity, which can be measured photometrically. The degree of turbidity is directed proportional to the <abbrev xlink:title="C-reactive protein">CRP</abbrev> concentration in the sample <sup>[<xref ref-type="bibr" rid="B21">21</xref>]</sup>.</p>
      <p>Exclusion criteria for the study were: known or suspected neoplasm, operative treatment/trauma in the last month, active and severe chronic obstructive pulmonary disease, chronic renal failure with GFR &lt;30 ml/min/m2, experienced stroke or other cerebral disease, which makes it difficult to assess the presence and degree of hepatic encephalopathy, long-standing diabetes mellitus with suspicion of pronounced proteinuria, conditions of hypoaldosteronism, hypothyroidism, diseases that are associated with chronic inflammation, immune dysregulation and the need for immunosuppressive therapy (systemic connective tissue disease, known immune deficiencies, chronic glomerulonephritis, ulcerative colitis, etc.). Hypoaldosteronism was ruled out by lab tests; hypothyroidism was ruled out by lacking clinical history and signs of disease, also by normal thyroid tests in nearly one third of cirrhosis patients.</p>
      <p>The statistical analysis included parametric (χ2- test, Fischer exact tests), non-parametric analyses (t – test – for the variables with normal distribution; Mann-Whitney U test - for the variables without normal distribution) of The correlation analysis included Perasion rho rank correlation was used when the variables were with normal distribution Spearman correlation, a nonparametric measure of the strength and direction of association was applied when there was at least one variable without normal distribution.</p>
    </sec>
    <sec sec-type="Results" id="sec5">
      <title>Results</title>
      <p>Patients with cirrhosis show more frequent anemia, lower hemoglobin, higher heart rates and higher levels of <abbrev xlink:title="C-reactive protein">CRP</abbrev> (while <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> were similar in cirrhosis and <abbrev xlink:title="chronic coronary disease">CAD</abbrev>). The patients with stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev> in our study showed worse renal function (Table <xref ref-type="table" rid="T1">1</xref>). The minimal and maximal repolarisation periods were much longer in cirrhosis compared to stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev> patients (Table <xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap id="T1" position="float" orientation="portrait">
        <label>Table 1.</label>
        <caption>
          <p>Characteristics of patients with cirrhosis and <abbrev xlink:title="chronic coronary disease">CAD</abbrev>, comparison.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>Disease/variable</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>Cirrhosis n=19</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold><abbrev xlink:title="chronic coronary disease">CAD</abbrev> n=19</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>p</bold>
              </th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age, years</td>
              <td rowspan="1" colspan="1">58.3±14.4</td>
              <td rowspan="1" colspan="1">63±13.1</td>
              <td rowspan="1" colspan="1">0.326</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hypertension</td>
              <td rowspan="1" colspan="1">12 (66.7%)</td>
              <td rowspan="1" colspan="1">18 (90%)</td>
              <td rowspan="1" colspan="1">0.117</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diabetes mellitus</td>
              <td rowspan="1" colspan="1">7 (38.9%)</td>
              <td rowspan="1" colspan="1">4 (20%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Anemia</td>
              <td rowspan="1" colspan="1">16 (88.9%)</td>
              <td rowspan="1" colspan="1">7 (35.6%)</td>
              <td rowspan="1" colspan="1">0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chronic kidney disease</td>
              <td rowspan="1" colspan="1">5 (26.3%)</td>
              <td rowspan="1" colspan="1">18 (72%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Creatinine</td>
              <td rowspan="1" colspan="1">94.6±35.3</td>
              <td rowspan="1" colspan="1">150.9±151.3</td>
              <td rowspan="1" colspan="1">0.199</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GFR, ml/min/m<sup>2</sup></td>
              <td rowspan="1" colspan="1">81.2±25.9</td>
              <td rowspan="1" colspan="1">62.1±23.9</td>
              <td rowspan="1" colspan="1">0.030</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hemoglobin</td>
              <td rowspan="1" colspan="1">102.5±31</td>
              <td rowspan="1" colspan="1">133.8±20.8</td>
              <td rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Procalcitonin</td>
              <td rowspan="1" colspan="1">0.86 (0.18 - 4.41)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="acute myocardial infarction">WBC</abbrev>
              </td>
              <td rowspan="1" colspan="1">6.9±1.7</td>
              <td rowspan="1" colspan="1">8.3±2.2</td>
              <td rowspan="1" colspan="1">0.292</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="C-reactive protein">CRP</abbrev>
              </td>
              <td rowspan="1" colspan="1">1.74 (0.14-5.3)</td>
              <td rowspan="1" colspan="1">0.34 (0.06-3.7)</td>
              <td rowspan="1" colspan="1">0.035</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Heart rate</td>
              <td rowspan="1" colspan="1">77.6±13.6</td>
              <td rowspan="1" colspan="1">71±9.9</td>
              <td rowspan="1" colspan="1">0.077</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmin</td>
              <td rowspan="1" colspan="1">445.4±58.7</td>
              <td rowspan="1" colspan="1">401.7±44.9</td>
              <td rowspan="1" colspan="1">0.011</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmax</td>
              <td rowspan="1" colspan="1">548±42.9</td>
              <td rowspan="1" colspan="1">505.8±42.9</td>
              <td rowspan="1" colspan="1">0.003</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="QT dispersion">QTcd</abbrev>
              </td>
              <td rowspan="1" colspan="1">123.6±35.7</td>
              <td rowspan="1" colspan="1">100.1±33.9</td>
              <td rowspan="1" colspan="1">0.188</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LV ejection fraction</td>
              <td rowspan="1" colspan="1">47±7.7</td>
              <td rowspan="1" colspan="1">52.2±11.3</td>
              <td rowspan="1" colspan="1">0.292</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ß-blocker</td>
              <td rowspan="1" colspan="1">9 (47.4%)</td>
              <td rowspan="1" colspan="1">11 (52.4%)</td>
              <td rowspan="1" colspan="1">1.000</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Aldosterone antagonist</td>
              <td rowspan="1" colspan="1">11 (57.9%)</td>
              <td rowspan="1" colspan="1">0 %</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FIB4index</td>
              <td rowspan="1" colspan="1">2.2 (1 - 13.4)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ChildPugh</td>
              <td rowspan="1" colspan="1">6.7±1.3</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev>
              </td>
              <td rowspan="1" colspan="1">14.7±5.5</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Patients with cirrhosis were with lower hemoglobin, higher heart rates, much longer minimal and maximal repolarisation periods, higher dispersion of repolarisation compared to the patients with acute myocardial infarction, <abbrev xlink:title="acute myocardial infarction">AMI</abbrev> (Table <xref ref-type="table" rid="T2">2</xref>).</p>
      <table-wrap id="T2" position="float" orientation="portrait">
        <label>Table 2.</label>
        <caption>
          <p>Characteristics of patients with cirrhosis and acute myocardial infarction, comparison.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>Disease/variable</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>Cirrhosis n=19</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold><abbrev xlink:title="chronic coronary disease">CAD</abbrev> n=19</bold>
              </th>
              <th rowspan="1" colspan="1">
                <bold>p</bold>
              </th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age, years</td>
              <td rowspan="1" colspan="1">58.3±14.4</td>
              <td rowspan="1" colspan="1">61±13.3</td>
              <td rowspan="1" colspan="1">0.223</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hypertension</td>
              <td rowspan="1" colspan="1">12 (66.7%)</td>
              <td rowspan="1" colspan="1">19 (100%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Diabetes mellitus</td>
              <td rowspan="1" colspan="1">7 (38.9%)</td>
              <td rowspan="1" colspan="1">6 (28.6%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Anemia</td>
              <td rowspan="1" colspan="1">16 (88.9%)</td>
              <td rowspan="1" colspan="1">2 (11.1%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Creatinine</td>
              <td rowspan="1" colspan="1">94.6±35.3</td>
              <td rowspan="1" colspan="1">109.0±87</td>
              <td rowspan="1" colspan="1">0.252</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GFR, ml/min/m2</td>
              <td rowspan="1" colspan="1">81.2±25.9</td>
              <td rowspan="1" colspan="1">79.1±27.7</td>
              <td rowspan="1" colspan="1">0.233</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hemoglobin</td>
              <td rowspan="1" colspan="1">97 (62-151)</td>
              <td rowspan="1" colspan="1">143 (122-197)</td>
              <td rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="acute myocardial infarction">WBC</abbrev>
              </td>
              <td rowspan="1" colspan="1">7.4 (3.9-8.9)</td>
              <td rowspan="1" colspan="1">9 (6.1-13.4)</td>
              <td rowspan="1" colspan="1">0.127</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="C-reactive protein">CRP</abbrev>
              </td>
              <td rowspan="1" colspan="1">1.3 (0.14-7.0)</td>
              <td rowspan="1" colspan="1">1.9 (0.7-16.7)</td>
              <td rowspan="1" colspan="1">0.121</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Heart rate</td>
              <td rowspan="1" colspan="1">77.6±13.6</td>
              <td rowspan="1" colspan="1">70.8±13.9</td>
              <td rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmin</td>
              <td rowspan="1" colspan="1">445.4±58.7</td>
              <td rowspan="1" colspan="1">380.9±37.1</td>
              <td rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmax</td>
              <td rowspan="1" colspan="1">548±42.9</td>
              <td rowspan="1" colspan="1">468.5±43.1</td>
              <td rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="QT dispersion">QTcd</abbrev>
              </td>
              <td rowspan="1" colspan="1">123.6±35.7</td>
              <td rowspan="1" colspan="1">89.9±26.6</td>
              <td rowspan="1" colspan="1">0.029</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LV ejection fraction</td>
              <td rowspan="1" colspan="1">47±7.7</td>
              <td rowspan="1" colspan="1">51.4±10.4</td>
              <td rowspan="1" colspan="1">0.634</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ß-blocker</td>
              <td rowspan="1" colspan="1">10 (27%)</td>
              <td rowspan="1" colspan="1">5 (26.3%)</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Aldosterone antagonist</td>
              <td rowspan="1" colspan="1">11 (57.9%)</td>
              <td rowspan="1" colspan="1">0 %</td>
              <td rowspan="1" colspan="1">NS</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="Markers inflammation, indices of repolarisation and prognosis in alcohol liver disease and stable CAD" id="sec6">
      <title>Markers inflammation, indices of repolarisation and prognosis in alcohol liver disease and stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev></title>
      <p>Higher <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> were marginally related with shorter minimal repolarisation periods in <abbrev xlink:title="acute myocardial infarction">AMI</abbrev>. The higher <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> tend to correlated with non-homogenous repolarization in cirrhosis and were significantly associated with dispersion of repolarisation in <abbrev xlink:title="acute myocardial infarction">AMI</abbrev> (Table <xref ref-type="table" rid="T3">3</xref>, Figs <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>).</p>
      <fig id="F1">
        <object-id content-type="doi">10.3897/bsms.8.154296.figure1</object-id>
        <object-id content-type="arpha">CF676B3D-00D2-58F0-B797-D35B88CE8D3C</object-id>
        <label>Figure 1.</label>
        <caption>
          <p><abbrev xlink:title="QT dispersion">QTcd</abbrev> and markers of inflammation in patients with cirrhosis on therapy.</p>
        </caption>
        <graphic xlink:href="bsms-08-001_article-154296__-g001.jpg" id="oo_1541860.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1541860</uri>
        </graphic>
      </fig>
      <fig id="F2">
        <object-id content-type="doi">10.3897/bsms.8.154296.figure2</object-id>
        <object-id content-type="arpha">E18AC187-6427-5905-92ED-555D0D1B1B99</object-id>
        <label>Figure 2.</label>
        <caption>
          <p><abbrev xlink:title="QT dispersion">QTcd</abbrev> and markers of inflammation in patients in acute myocardial infarction.</p>
        </caption>
        <graphic xlink:href="bsms-08-001_article-154296__-g002.jpg" id="oo_1541861.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1541861</uri>
        </graphic>
      </fig>
      <table-wrap id="T3" position="float" orientation="portrait">
        <label>Table 3.</label>
        <caption>
          <p><abbrev xlink:title="acute myocardial infarction">WBC</abbrev>, repolarization indices and other prognostic markers, correlation analysis.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>Disease/variable</bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>Cirrhosis</bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>
                  <abbrev xlink:title="chronic coronary disease">CAD</abbrev>
                </bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>
                  <abbrev xlink:title="acute myocardial infarction">AMI</abbrev>
                </bold>
              </th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>
                  <abbrev xlink:title="acute myocardial infarction">WBC</abbrev>
                </bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age</td>
              <td rowspan="1" colspan="1">0.153</td>
              <td rowspan="1" colspan="1">0.272</td>
              <td rowspan="1" colspan="1">-0.187</td>
              <td rowspan="1" colspan="1">0.442</td>
              <td rowspan="1" colspan="1">-0.215</td>
              <td rowspan="1" colspan="1">0.194</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="C-reactive protein">CRP</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.120</td>
              <td rowspan="1" colspan="1">0.318</td>
              <td rowspan="1" colspan="1">-0.010</td>
              <td rowspan="1" colspan="1">0.971</td>
              <td rowspan="1" colspan="1">0,150</td>
              <td rowspan="1" colspan="1">0,723</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Heart rate</td>
              <td rowspan="1" colspan="1">-0.076</td>
              <td rowspan="1" colspan="1">0.389</td>
              <td rowspan="1" colspan="1">0.014</td>
              <td rowspan="1" colspan="1">0.951</td>
              <td rowspan="1" colspan="1">0.084</td>
              <td rowspan="1" colspan="1">0.370</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmin</td>
              <td rowspan="1" colspan="1">-0,220</td>
              <td rowspan="1" colspan="1">0.206</td>
              <td rowspan="1" colspan="1">-0.076</td>
              <td rowspan="1" colspan="1">0.771</td>
              <td rowspan="1" colspan="1">-0.370</td>
              <td rowspan="1" colspan="1">0.056</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmax</td>
              <td rowspan="1" colspan="1">0.152</td>
              <td rowspan="1" colspan="1">0.287</td>
              <td rowspan="1" colspan="1">0.064</td>
              <td rowspan="1" colspan="1">0.806</td>
              <td rowspan="1" colspan="1">0.179</td>
              <td rowspan="1" colspan="1">0.239</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="QT dispersion">QTcd</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.352</td>
              <td rowspan="1" colspan="1">0.091</td>
              <td rowspan="1" colspan="1">0.116</td>
              <td rowspan="1" colspan="1">0.657</td>
              <td rowspan="1" colspan="1">0.562</td>
              <td rowspan="1" colspan="1">0.008</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LV ejection fraction</td>
              <td rowspan="1" colspan="1">-0.300</td>
              <td rowspan="1" colspan="1">0.129</td>
              <td rowspan="1" colspan="1">0.351</td>
              <td rowspan="1" colspan="1">0.200</td>
              <td rowspan="1" colspan="1">-0.211</td>
              <td rowspan="1" colspan="1">0.200</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FIB4index</td>
              <td rowspan="1" colspan="1">-0.223</td>
              <td rowspan="1" colspan="1">0.187</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ChildPugh</td>
              <td rowspan="1" colspan="1">-0.263</td>
              <td rowspan="1" colspan="1">0.146</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.207</td>
              <td rowspan="1" colspan="1">0.205</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Higher <abbrev xlink:title="C-reactive protein">CRP</abbrev> were related as tendency with shorter minimal repolarisation periods, longer maximal repolarisation periods and correlated significantly positively with higher dispersion of repolarisation in <abbrev xlink:title="acute myocardial infarction">AMI</abbrev> (Fig. <xref ref-type="fig" rid="F2">2</xref>). The higher <abbrev xlink:title="C-reactive protein">CRP</abbrev> also correlated with prolonged maximal repolarization in stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev> (Table <xref ref-type="table" rid="T4">4</xref>). <abbrev xlink:title="C-reactive protein">CRP</abbrev> was not associated with repolarisation in the subset of patients with cirrhosis, according to this analysis (Table <xref ref-type="table" rid="T4">4</xref>, Fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
      <table-wrap id="T4" position="float" orientation="portrait">
        <label>Table 4.</label>
        <caption>
          <p><abbrev xlink:title="C-reactive protein">CRP</abbrev>, repolarization indices and other prognostic markers, correlation analysis.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>Disease/variable</bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>Cirrhosis</bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>
                  <abbrev xlink:title="chronic coronary disease">CAD</abbrev>
                </bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>
                  <abbrev xlink:title="acute myocardial infarction">AMI</abbrev>
                </bold>
              </th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>
                  <abbrev xlink:title="C-reactive protein">CRP</abbrev>
                </bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age</td>
              <td rowspan="1" colspan="1">0.065</td>
              <td rowspan="1" colspan="1">0.797</td>
              <td rowspan="1" colspan="1">0.046</td>
              <td rowspan="1" colspan="1">0.860</td>
              <td rowspan="1" colspan="1">0.245</td>
              <td rowspan="1" colspan="1">0.156</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Heart rate</td>
              <td rowspan="1" colspan="1">0.154</td>
              <td rowspan="1" colspan="1">0.568</td>
              <td rowspan="1" colspan="1">0.314</td>
              <td rowspan="1" colspan="1">0.237</td>
              <td rowspan="1" colspan="1">0.270</td>
              <td rowspan="1" colspan="1">0.130</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmin</td>
              <td rowspan="1" colspan="1">-0.243</td>
              <td rowspan="1" colspan="1">0.364</td>
              <td rowspan="1" colspan="1">0.510</td>
              <td rowspan="1" colspan="1">0.044</td>
              <td rowspan="1" colspan="1">-0.371</td>
              <td rowspan="1" colspan="1">0.059</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmax</td>
              <td rowspan="1" colspan="1">-0.180</td>
              <td rowspan="1" colspan="1">0.494</td>
              <td rowspan="1" colspan="1">0.523</td>
              <td rowspan="1" colspan="1">0.037</td>
              <td rowspan="1" colspan="1">0.317</td>
              <td rowspan="1" colspan="1">0.093</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="QT dispersion">QTcd</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.057</td>
              <td rowspan="1" colspan="1">0.833</td>
              <td rowspan="1" colspan="1">0.019</td>
              <td rowspan="1" colspan="1">0.916</td>
              <td rowspan="1" colspan="1">0.711</td>
              <td rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LV ejection fraction</td>
              <td rowspan="1" colspan="1">0.285</td>
              <td rowspan="1" colspan="1">0.215</td>
              <td rowspan="1" colspan="1">0.350</td>
              <td rowspan="1" colspan="1">0.241</td>
              <td rowspan="1" colspan="1">-0.471</td>
              <td rowspan="1" colspan="1">0.024</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FIB4index</td>
              <td rowspan="1" colspan="1">-0.200</td>
              <td rowspan="1" colspan="1">0.426</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ChildPugh</td>
              <td rowspan="1" colspan="1">0.198</td>
              <td rowspan="1" colspan="1">0.432</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.235</td>
              <td rowspan="1" colspan="1">0.348</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Higher <abbrev xlink:title="procalcitonin">PCT</abbrev> correlated significantly with higher heart rates and tended to correlate with greater severity of cirrhosis (Table <xref ref-type="table" rid="T5">5</xref>).</p>
      <table-wrap id="T5" position="float" orientation="portrait">
        <label>Table 5.</label>
        <caption>
          <p>Procalcitonin correlation with repolarization indices and other prognostic markers in patients with cirrhosis.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">
                <bold>Disease</bold>
              </th>
              <th rowspan="1" colspan="2">
                <bold>Cirrhosis</bold>
              </th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Procalcitonin</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>r</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>p</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Heart rate</td>
              <td rowspan="1" colspan="1">0.507</td>
              <td rowspan="1" colspan="1">0.022</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmin</td>
              <td rowspan="1" colspan="1">-0.094</td>
              <td rowspan="1" colspan="1">0.365</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">QTcmax</td>
              <td rowspan="1" colspan="1">0.158</td>
              <td rowspan="1" colspan="1">0.280</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="QT dispersion">QTcd</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.199</td>
              <td rowspan="1" colspan="1">0.230</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LV ejection fraction</td>
              <td rowspan="1" colspan="1">0.268</td>
              <td rowspan="1" colspan="1">0.158</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FIB4index</td>
              <td rowspan="1" colspan="1">0.137</td>
              <td rowspan="1" colspan="1">0.294</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ChildPugh</td>
              <td rowspan="1" colspan="1">0.330</td>
              <td rowspan="1" colspan="1">0.077</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="model of end-stage liver disease">MELD</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.001</td>
              <td rowspan="1" colspan="1">0.499</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Age was related with left ventricular (LV) systolic function (LV ejection fraction, LV EF). This correlation was inverse. It was a tendency and was observed only among the patients with coronary disease (p=- 0.476, p=0.062). Neither duration of repolarisation, dispersion of repolarisation nor any other variable showed significant correlation with age in the small groups with cirrhosis and coronary disease compared in our study.</p>
    </sec>
    <sec sec-type="Discussion" id="sec7">
      <title>Discussion</title>
      <p>The presented cohorts with cirrhosis and stable <abbrev xlink:title="chronic coronary disease">CAD</abbrev> differed by higher incidence of acute infectious disease at admission. The levels of <abbrev xlink:title="C-reactive protein">CRP</abbrev> remained higher in the cirrhosis group after 7–10 days of antimicrobial treatment. Anemia was more commonly diagnosed in the group with cirrhosis in contrast to <abbrev xlink:title="chronic coronary disease">CAD</abbrev>. The therapy with β-blocker was underused in the settings of cirrhosis. Consistently, the heart rates of our patients with cirrhosis tended to be substantially higher compared to the patients with <abbrev xlink:title="chronic coronary disease">CAD</abbrev>. Most often, the patients with cirrhosis and clinically significant portal hypertension have more advanced hyperdynamic circulation than do those without severe portal hypertension <sup>[<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B22">22</xref>]</sup>. Thus, a much greater hepatic venous pressure gradient reduction by β-blockers is expected in patients with clinically significant portal hypertension than in those without <sup>[<xref ref-type="bibr" rid="B22">22</xref>]</sup>. The main determinants of the corrected QT interval and the corrected dispersion of repolarization are the systolic and diastolic function of left ventricle and the activation of the autonomic nervous system <sup>[<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B3">3</xref>]</sup>. The reduction of <abbrev xlink:title="QT dispersion">QTcd</abbrev> by β-blockers suggests a prophylactic effect of β-blockers regarding severe arrhythmias due to inhomogeneous ventricular repolarization. Beta-blockers shorten QTc in cirrhosis similar to <abbrev xlink:title="chronic coronary disease">CAD</abbrev><sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>. We can speculate that unopposed sympathetic system overactivity augmented during acute infection could be confounding factor which contributed to an association of certain inflammatory markers (white blood cells) with dispersion of repolarisation and arrhythmia risk in the group with cirrhosis to in contrast to <abbrev xlink:title="chronic coronary disease">CAD</abbrev>. Higher heart rates lead to shorter minimal repolarisation periods and thus to increased <abbrev xlink:title="QT dispersion">QTcd</abbrev>. In addition, repolarisation period increases in cirrhosis complicated with gastrointestinal bleeding or infection possibly due to overt cardiac ischemia <sup>[<xref ref-type="bibr" rid="B23">23</xref>]</sup>. The prevalence myocardial injury in patients with infectious disease was found to be up to 36% <sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup>. According to previous studies, markers of cardiac dysfunction (hs-TnT) and inflammation (<abbrev xlink:title="C-reactive protein">CRP</abbrev>) were significantly associated with severity in liver disease, degree of portal hypertension and survival in cirrhosis <sup>[<xref ref-type="bibr" rid="B23">23</xref>]</sup>. Provided that there was high rate of infectious complications in the investigated cohorts, we tested for significance the association of markers of inflammation with left ventricular systolic function in cirrhosis. Troponin was assessed in few patients with cirrhosis in the cohort with cirrhosis analysed and we found out that troponin values varied within reference limits. Any substantial correlation of <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> with left ventricular ejection function was not found. Despite that, <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> at the time of cirrhosis decompensation emerged as predictor of non-homogenous repolarisation, and thus of arrythmia risk.</p>
      <p>We observed a positive correlation of the dispersion of repolarisation with <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> in the group of patients with cirrhosis and a lack of correlation with <abbrev xlink:title="C-reactive protein">CRP</abbrev> in the same cohort. This correlation could be marker of ongoing remote myocardial ischemia secondary to chronic anaemia and hyperkinetic circulation in patients with cirrhosis and acute infection rather than to co-morbid coronary artery disease. There are two reasons supporting such hypothesis. First, the existing literature link higher <abbrev xlink:title="C-reactive protein">CRP</abbrev> with prolongation of QTc interval exclusively in patients with coronary artery disease only in the settings of systemic inflammatory conditions such as sepsis and COVID-19 infection <sup>[<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>]</sup>. Secondly, the site of production and the site of metabolism of <abbrev xlink:title="C-reactive protein">CRP</abbrev> are still not well defined <sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup>. Currently, it is thought that <abbrev xlink:title="C-reactive protein">CRP</abbrev> is produced exclusively by hepatocytes and human macrophages. Nevertheless, studies suggest a variety of other sites of production of <abbrev xlink:title="C-reactive protein">CRP</abbrev> by locally distributed macrophages including coronary-arteries, inflamed kidneys, adipose tissue <sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup>. In coronary disease, macrophages accumulate with expansion of the lipid core of atherosclerotic plaques <sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup> and increase further at the time of acute coronary plaque rupture and thrombosis. The significant elevation of <abbrev xlink:title="C-reactive protein">CRP</abbrev> levels reported after 48 hours of plaque rupture in acute myocardial infarction (<abbrev xlink:title="acute myocardial infarction">AMI</abbrev>) <sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup> was proved to be due to response of immune system to myocardial necrosis. Myocardial ischemia leads to higher QT dispersion. The latter aids in diagnosing acute coronary syndrome in patients presenting with chest pain <sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup>. Also, there is inverse correlation between the size of myocardial infarction (assessed by the elevation in cardiac enzymes) with QT dispersion in patients with non-ST elevation myocardial infarction <sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup>. We also obtained strong <abbrev xlink:title="C-reactive protein">CRP</abbrev>-<abbrev xlink:title="QT dispersion">QTcd</abbrev> correlation (r=0.711, p&lt;0.0001). Possible confounder of this association is the developed phase of inflammatory response to the infarct zone. <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> were measured immediately after percutaneous intervention. In the patient group with cirrhosis the initial treatment with antibiotics before obtaining blood samples for <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="procalcitonin">PCT</abbrev> blurred the relationship of <abbrev xlink:title="C-reactive protein">CRP</abbrev> with repolarisation indices. Other cause of significant correlation is the same location (the heart) of inflammatory response and the functional abnormality (increased dispersion of repolarisation) in the acute phase of myocardial infarction.</p>
      <p>We also confirm the significance of acute inflammation (<abbrev xlink:title="acute myocardial infarction">WBC</abbrev>, <abbrev xlink:title="C-reactive protein">CRP</abbrev>, procalcitonin) as factor for future complications in cirrhosis. The levels of circulating inflammatory molecules such as C-reactive protein and procalcitonin were elevated in patients with alcohol liver disease and cirrhosis. Assessment of plasma levels of <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="procalcitonin">PCT</abbrev> directly correlated with prognosis in cirrhosis <sup>[<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]</sup>.</p>
      <p>The correlation of procalcitonin with heart rate (r=0.507, p=0.022) is interesting and novel finding in this study. Discrepancies between plasma <abbrev xlink:title="procalcitonin">PCT</abbrev> and <abbrev xlink:title="C-reactive protein">CRP</abbrev> levels are common in acute illness. <abbrev xlink:title="procalcitonin">PCT</abbrev> is elevated in bacterial infections and sepsis and may help. in discriminating between bacterial infection and immune system activation (e.g. in an autoimmune disease). Higher heart rates are characteristic feature of bacterial infection in which <abbrev xlink:title="procalcitonin">PCT</abbrev> is elevated. However, the relationship <abbrev xlink:title="procalcitonin">PCT</abbrev> and heart rate could be more complex and possibly includes sympathetic autonomic nervous system activation.</p>
    </sec>
    <sec sec-type="Conclusions" id="sec8">
      <title>Conclusions</title>
      <p>The count of white blood cells and procalcitonin is associated with the severity in alcoholic liver disease and the risk of complications. In patients with cirrhosis and infection, <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> is specific marker of increased dispersion of repolarisation. In contrast to cirrhosis, <abbrev xlink:title="C-reactive protein">CRP</abbrev> is associated with the risk of ventricular arrhythmias in stable coronary disease, while both <abbrev xlink:title="C-reactive protein">CRP</abbrev> and <abbrev xlink:title="acute myocardial infarction">WBC</abbrev> correlated with repolarisation indices in acute myocardial infarction. Treatment with ß-blockers could reduce the risk of arrhythmia in patients with cirrhosis.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>This analysis received approval by the Committee of Ethics of University Emergency Medicine Hospital ‘Pirogov’ as part of a research project ‘Gonadal steroids as epiphenomenon of inflammation in patients with alcoholic liver disease’ (incoming № EK-12-24/07-11-2024). The laboratory assessment of procalcitonin was funded by the leading researcher N. Semerdzhieva. The laboratory assessment of C-reactive protein in the group with acute myocardial infarction used as control group received funding by Medical University-Sofia; as part of previous research project ‘Gender-related differences in acute coronary syndrome: significance of gonadal steroids, oxidative stress and inflammation’ (‘Young researcher-2012’ Project; contract number D-5/2012; project with incoming № 35/12-2011)..</p>
    </ack>
    <sec sec-type="Additional information" id="sec9">
      <title>Additional information</title>
      <p>
        <bold>Conflict of interest</bold>
      </p>
      <p>The authors have declared that no competing interests exist.</p>
      <p>
        <bold>Ethical statements</bold>
      </p>
      <p>Clinical trials: Approval by the Committee of Ethics of University Emergency Medicine Hospital ‘Pirogov’ as part of a research project ‘Gonadal steroids as epiphenomenon of inflammation in patients with alcoholic liver disease’ (incoming № EK-12-24/07-11-2024.</p>
      <p>The authors declared that no experiments on humans or human tissues were performed for the present study.</p>
      <p>Informed consent from the humans, donors or donors’ representatives: The signed informed concents are kept by the leading researcher. Blind copies of all informed concents can be made availabe upon request to the journal.</p>
      <p>The authors declared that no experiments on animals were performed for the present study.</p>
      <p>The authors declared that no commercially available immortalised human and animal cell lines were used in the present study.</p>
      <p>
        <bold>Use of AI</bold>
      </p>
      <p>No use of AI was reported.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>No funding was reported.</p>
      <p>
        <bold>Author contributions</bold>
      </p>
      <p>Conceptualization: NE. Data curation: DS, MC, RT, II, DD, NE, SS, KK, YK, MP. Formal analysis: YK, MC, DS, DD, NE, KK, RT, II, MMS, SS, MP. Funding acquisition: NE. Investigation: MMS, KK, NE, YK, MC, MP, SS, II, RT, DD, DS. Methodology: DD, KK, NE, SS. Project administration: DS, MC. Resources: MMS, RT, MC, KK, SS. Software: RT, NE. Supervision: MP, DD, II. Validation: DS, DD, YK, MC, MP, NE, MMS, RT, KK. Visualization: SS, DS. Writing - original draft: NE. Writing - review and editing: MP, SS, KK, II, MMS, RT, DD, MC, DS, YK.</p>
      <p>
        <bold>Author ORCIDs</bold>
      </p>
      <p>Niya Emilova <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-1878-9807">https://orcid.org/0000-0003-1878-9807</ext-link></p>
      <p>Dobrinka Dineva <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0009-0005-1019-128X">https://orcid.org/0009-0005-1019-128X</ext-link></p>
      <p>
        <bold>Data availability</bold>
      </p>
      <p>All of the data that support the findings of this study are available in the main text or Supplementary Information.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation>Sredniawa B, Musialik-Lydka A, Pasyk S. Measurement dispersion of the QT interval and its significance in different diseases. Pol Merkur Lek 2001;11(61):52-55. <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/11579833/">https://pubmed.ncbi.nlm.nih.gov/11579833/</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation>Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007;25(11):2345-51. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1097/HJH.0b013e3282e9a72d">https://doi.org/10.1097/HJH.0b013e3282e9a72d</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation>Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ. Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 2011;108(12):1760-1766. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.amjcard.2011.07.050">https://doi.org/10.1016/j.amjcard.2011.07.050</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation>Musha H, So T, Hashimoto N, Eto F, Ozawa A, Kunishima T, Murayama M. Dynamic changes of QT dispersion as a predictor of myocardial ischemia on exercise testing in patients with angina pectoris. Jpn Heart J 1999;40(2):119-126. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1536/jhj.40.119">https://doi.org/10.1536/jhj.40.119</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation>Pekdemir M, Karaca I, Cevik Y, Yanturali S, Ilkay E. The diagnostic value of QT dispersion for acute coronary syndrome in patients presenting with chest pain and nondiagnostic initial electrocardiograms. Mt Sinai J Med 2006;73(5):813-817. <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17008945/">https://pubmed.ncbi.nlm.nih.gov/17008945/</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation>Jensen CJ, Lusebrink S, Wolf A, Schlosser T, Nassenstein K, Naber CK, Sabin GV, Bruder O. Reduction of QTd - a novel marker for successful reperfusion in NSTEMI. Pathophysiologic Insights by CMR. Int J Med Sci 2015; 12(5):378-386. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.7150/ijms.11224">https://doi.org/10.7150/ijms.11224</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation>Bazoukis G, Yeung C, Ho RWH, Varrias D, Papadatis S, Lee S, Li KHC, Sakelleropoulou A, Saplaouras A, Kisoulis P, Vlachos K, Lampropoulos K, Thomopoulos C, Letsas KP, Liu T, Tse G. Association of QT dispersion with mortality and arrhythmic events-A meta-analysis of observational studies. J Arrhythm 2019;36(1):105-115. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1002/joa3.12253">https://doi.org/10.1002/joa3.12253</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation>Reant P, Chasseriaud W, Pillois X, Dijos M, Arsac F, Roudaut R, Lafitte S. Early detection of left ventricular systolic dysfunction using two-dimensional speckle tracking strain evaluation in healthy subjects after acute alcohol intoxication. Echocardiography 2012; 29 (8): 887-1010. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1111/j.1540-8175.2012.01717.x">https://doi.org/10.1111/j.1540-8175.2012.01717.x</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation>Kronborg TM, Webel H, O’Connel MB, Danielsen KV, Hobolt L, Møller S, Jensen RT, Bendtsen F, Hansen T, Rasmussen S, Juel HB, Kimer N. Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study. Sci Rep 13, 20039 (2023). <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1038/s41598-023-47384-2">https://doi.org/10.1038/s41598-023-47384-2</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation>Béjar-Serrano S, del Pozo P, Fernández-de la Varga M, Benlloch S. Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital. Gastroenterol Hepatol. 2019;42(4):228-238. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.gastre.2019.03.010">https://doi.org/10.1016/j.gastre.2019.03.010</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation>Winkler C, Hobolth L, Krag A, Bendtsen F, Møller S. Effects of treatment with β-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis. Eur J Gastroenterol Hepatol. 2011;23(4):334-342. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1097/MEG.0b013e3283455b7f">https://doi.org/10.1097/MEG.0b013e3283455b7f</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation>Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110-122. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1055/s-2008-1040325">https://doi.org/10.1055/s-2008-1040325</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation>Lazzerini PE, Acampa M, Laghi-Pasini F, Bertolozzi I, Finizola F, Vanni F, Natale M, Bisogno S, Cevenini G, Cartocci A, Giabbari B, Migliacci N, D’Errico A, Dokollari, Maccherini M, Boutidir M,Capecchi PL. Cardiac arrest risk during acute infections: systemic inflammation directly prolongs QTc interval via cytokine-mediated effects on potassium channel expression. Circ Arrhythm Electrophysiol. 2020; 13:e008627. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1161/CIRCEP.120.008627">https://doi.org/10.1161/CIRCEP.120.008627</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation>Viscido A, Capannolo A, Petroni R, Stefanelli G, Zerboni G, De Martinis M, Necozione S, Penco M, Frieri G, Latella G, Romano S. Association between corrected QT interval and c-reactive protein in patients with inflammatory bowel diseases. Medicina 2020, 56(8), 382. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3390/medicina56080382">https://doi.org/10.3390/medicina56080382</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation>Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: Tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken) 2015; 67: 332-339. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1002/acr.22455">https://doi.org/10.1002/acr.22455</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation>Peng DQ, Zhao SP, Chen Y, Li XP. Effect of bisoprolol on QT dispersion in patients with congestive heart failure-the etiology-dependent response. Int J Cardiol 2001;77(2-3):141-148. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/S0167-5273(00)00452-6">https://doi.org/10.1016/S0167-5273(00)00452-6</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation>Shehab A, Elnour AA and Struthers AD. A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr 2008;19(6):292-296. <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19104723/">https://pubmed.ncbi.nlm.nih.gov/19104723/</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation>Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1053/he.2000.5852">https://doi.org/10.1053/he.2000.5852</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation>Chirapongsathorn S, Bunraksa W, Chaiprasert A, Punpanich D, Supasyndh O, Kamath PS. Adding C-reactive protein and procalcitonin to the MELD score improves mortality prediction in patients with complications of cirrhosis. J Gastroenterol Hepatol. 2018;33(3):726-732. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1111/jgh.13928">https://doi.org/10.1111/jgh.13928</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation>Hubl W, Krassler J, Zingler C, Pertschy A, Hentschel J, Gerhards-Reich C, Mack M, Demant T. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab. 2003;49(7-8):319-327. <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12908732/">https://pubmed.ncbi.nlm.nih.gov/12908732/</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation>Lolekhaa PH, Chittammaa A, Robertsb WL, Sritarac P, Cheepudomwitc S, Suriyawongpaisal P. Comparative study of two automated high-sensitivity C-reactive protein methods in a large population. Clin Biochem. 2005; 38: 31 - 35. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.clinbiochem.2004.09.001">https://doi.org/10.1016/j.clinbiochem.2004.09.001</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation>Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, Baňares R, Morillas RM, Poca M, Peňas B, Augistin S, Abraldes JG, Alvarado E, Torres F, Bosch J. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393(10181):1597-1608. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/S0140-6736(18)31875-0">https://doi.org/10.1016/S0140-6736(18)31875-0</ext-link></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation>Wiese S, Mortensen C, Gøtze JP, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int. 2014;34(6):e19-30. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1111/liv.12428">https://doi.org/10.1111/liv.12428</ext-link></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation>Chun TT, Garcia-Toca M, Eng JF, Slaiby J, Mercaccio EJ Jr, Cioffi WG, Heffernan DS. Postoperative infections are associated with increased risk of cardiac events in vascular patients. Ann Vasc Surg 2017: 41: 151-159. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.avsg.2016.09.026">https://doi.org/10.1016/j.avsg.2016.09.026</ext-link></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation>Isakadze N, Engels MC, Beer D, McClellan R, Yanek LR, Mondaloo B, Hays AG, Metkus TS, Calkins H, Barth AS. C-reactive Protein elevation is associated with QTc interval prolongation in patients hospitalized with COVID-19. Front Cardiovasc Med. 2022; 9:866146. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3389/fcvm.2022.866146">https://doi.org/10.3389/fcvm.2022.866146</ext-link></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation>Liu W, Shao R, Zhang S, Jin L, Liu R, Chen P, Hu J, Ma H, Wu B, Liang W, Luo X, Li JChen W, Xiong N, He B. Characteristics, predictors and outcomes of new-onset QT prolongation in sepsis: a multicentre retrospective study. Crit Care 2024; 28: 115. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1186/s13054-024-04879-2">https://doi.org/10.1186/s13054-024-04879-2</ext-link></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation>Pieri G, Agarwal B, Burroughs AK. C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol. 2014;27(2):113-120. <ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3982625/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3982625/</ext-link></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation>Murphy JG, Lloyd, MA. Mayo Clinic Cardiology: Concise Textbook. Pathogenesis of atherosclerosis. Vulnerability and rupture of plaque, 3rd ed 2007, Mayo Clinic Scientific Press and Informa Healthcare USA, Inc</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation>Reindl M, Reinstadler SJ, Feistritzer H, Klug G, Tiller C, Mair J, Mayr A, Jaschke W, Metzler B. Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016; 6: (7). <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1177/2048872616661691">https://doi.org/10.1177/2048872616661691</ext-link></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation>Elefsinoitis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, et al. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol. 2006;18(5):525-530. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1097/00042737-200605000-00012">https://doi.org/10.1097/00042737-200605000-00012</ext-link></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation>Sato S, Sato S, Tsuzura H, Ikeda Y, Sho H, Sho T, Amano N, Murata A, Shimada Y, Iijima K, Nagahara A, Genda T. Elevated serum procalcitonin levels and their association with the prognosis of patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020; 32(9);1222 -1228. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1097/MEG.0000000000001644">https://doi.org/10.1097/MEG.0000000000001644</ext-link></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation>Kodata S, Kashiura M, Moriya T. Procalcitonin elevation induced by sympathomimetic drug overdose. Acute Med Surg 2021 Aug 3;8(1):e687. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1002/ams2.687">https://doi.org/10.1002/ams2.687</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
